Observational studyPharmacoEconomics2020

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.

Elizabeth Wehler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.